ZIOPHARM Oncology, Inc. and Intrexon Corporation Announce Presentations at the 2013 American Association for Cancer Research-National Cancer Institute-EORTC International Conference
Published: Oct 17, 2013
BOSTON and GERMANTOWN, Md., Oct. 17, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the discovery and development of new cancer therapies, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced scheduled poster presentations at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is taking place October 19-23, 2013 in Boston. The conference is a joint meeting of the American Association for Cancer Research, the National Cancer Institute and the European Organisation for Research and Treatment of Cancer. The presentations will highlight studies conducted jointly between ZIOPHARM and Intrexon as part of an Exclusive Channel Collaboration to research, develop and commercialize novel in vivo DNA- and cell-based oncology therapeutics using different approaches, regulated by Intrexon's proprietary RheoSwitch Therapeutic System® (RTS®) platform.
Help employers find you! Check out all the jobs and post your resume.